AK

pharma, healthcare, pricing, reimbursement, market access, health economics

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

New report - Spotlight On Multiple Myeloma. Next-gen drugs have entered but personalised approaches remain limited http://t.co/84x5vzBMfx

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

Read the latest edition of our Spotlight On series, focussing on personalized therapies in non-small cell lung cancer http://t.co/Dq6u7ydS

[Guardian Healthcare @GdnHealthcare]

Our online Q&A at noon today will discuss #innovation in the #NHS. Find out more & leave your Qs here: http://t.co/1zd46Bid

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

Global pharma sales were $880 billion in 2011, with pharma co's reinvesting 2 - 25% of sales in R&D, according to our latest pharma factbook

[Clarivate for Life Sciences & Healthcare @ClarivateHealth]

UK prime minister #Cameron announces £180 million catalyst fund for proof of concept ideas to facilitate drug development #ftpharma

[AK @pharma_phairy]

@EuropeanCancer is there anything you can do to improve the performance of the website? it keeps crashing and refusing to open the abstacts!

[AK @pharma_phairy]

Follow @Cortellis from Thomson Reuters for #pharma news and conference snippets, as well as other analysis (yes I do work for them!) #FF

[AK @pharma_phairy]

big pharma M&A strategies result in loss of $1 trillion in value over last decade http://bit.ly/em8Nd0

[AK @pharma_phairy]

Affordability of pharmaceuticals should be considered within framework of total healthcare costs. Remains only ~15% of healthcare cost in UK

[AK @pharma_phairy]

Value-based pricing is a green light for pharmaceutical collaboration to improve outcomes

[AK @pharma_phairy]

The UK is the most sophisticated market in the world at assessing value

[AK @pharma_phairy]

Balancing access with sustainable affordability

[AK @pharma_phairy]

Rapidly expanding area of personalised medicine in the absence of evidence of improved outcomes

[AK @pharma_phairy]

Specialty pharmacy medications with ever increasing price tags often inversely proportional to value added

[AK @pharma_phairy]

Top 3 issues impacting pharmaceutical market access:

[AK @pharma_phairy]

@AnnemarieVtW that doesn't seem that much considering the top 12 biologics made ~$30 billion in 2010, and most coverage expires before 2015?

[AK @pharma_phairy]

@adamfeuerstein no chance!

[AK @pharma_phairy]

will Pfizer's copay offset program really maintain sales for Lipitor? fascinating

[AK @pharma_phairy]

@AnnemarieVtW have enjoyed your tweets on the subject

[AK @pharma_phairy]

@BioCrowd agreed!